Related Experiment Video
Updated: Jun 25, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis
Alexandra Maria Giovanna Brunasso1, Cesare Massone
1Department of Dermatology, Galliera Hospital, Genoa, Italy.
Background:
Thrombocytopenia has been reported to be associated with efalizumab therapy, but has only sporadically been reported with other anti-tumor necrosis factor alfa (TNF-alpha) agents.
Objective:
To describe the frequency of thrombocytopenia in a cohort of patients who underwent biological therapies for psoriasis.
Methods:
This was a retrospective observational study of 93 patients.
Results:
One hundred eighteen courses of biological therapies were administered to 93 patients. Four of 67 patients who received anti-TNF-alpha agents developed drug-induced thrombocytopenia during treatment, compared with none of the 51 patients receiving efalizumab therapy. The platelet count recovered after suspension of anti-TNF-alpha agents in 3 patients and relapsed after re-exposure in two patients. The overall estimated frequency of thrombocytopenia in our cohort was 4.30% (95% confidence interval [CI], 0% to 6.2%).
Limitations:
These findings should be validated in larger studies.
Conclusions:
Drug-induced thrombocytopenia is a potential side effect of anti-TNF-alpha agents. Immediate monitoring of platelet counts is recommended if autoimmunity is suspected.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Venous Thrombosis III: Interprofessional Care
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Anticoagulant Drugs: Low-Molecular-Weight Heparins